low-dose-rate brachytherapy + standard-of-care immunotherapy

This combination regimen, being evaluated by the Case Comprehensive Cancer Center, consists of low-dose-rate (LDR) brachytherapy administered alongside standard-of-care (SOC) immunotherapy. LDR brachytherapy involves the interstitial placement of radioactive sources directly into or near the tumor site to provide continuous, localized radiation. This is combined with systemic administration of FDA-approved immune checkpoint inhibitors, such as those targeting PD-1, PD-L1, or CTLA-4. The therapeutic rationale is based on the potential for localized radiation to enhance systemic anti-tumor immunity (the abscopal effect) and sensitize the tumor microenvironment to immunotherapy. The regimen is currently in a Phase 1 pilot study for patients with advanced (Stage III/IV) cutaneous melanoma, Stage IV renal cell carcinoma, and Stage IV urothelial carcinoma of the renal pelvis.

Other names

LDR Brachytherapy + ImmunotherapyLow-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibitionimmunotherapy-Case Comprehensive Cancer Center-cutaneous melanoma-renal cell carcinoma-urothelial carcinoma of renal pelvis